Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies: precision cellular therapy selectively deplete autoreactive B cells @MaxKonigMD in the plenary: CATCR can take out anti-b2GPI autoAbs crucial to antiphospholipid syndrome, but preserve normal B cells #ACR22 @RheumNow https://t.co/5ZLocrwqKY